Oncology Articles

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1
Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Standard Adjuvant Therapy for Melanoma Within Reach
Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.
Combination Therapies Push Melanoma Field Forward
Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.
Atezolizumab Triplet Achieves 75% CR Rate in Frontline Follicular Lymphoma
The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.
Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets
Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.
Combination Regimen Safe, Effective as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma. 
FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL
The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Most Patients in Need of HCT Can Now Get Transplants
Due to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.
Publication Bottom Border
Border Publication
x